Recommendations for thromboembolic disease in oncological processes. A view from primary care
Copyright © 2023 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved..
Venous thromboembolic disease (VTE) is a frequent complication in patients diagnosed with cancer and a cause of morbidity and mortality. Approximately 20% of thromboembolic episodes develop in association with active cancer. On the other hand, it is estimated that about 2-12% of cases, the thromboembolic episode is the first manifestation of an occult cancer, diagnosed at that time or subsequently, which offers an opportunity for early diagnosis and treatment. There are multiple factors that contribute to increase the risk of VTE in oncological patients in relation to specific characteristics of the patient, the tumor and the treatments. Knowledge of these risk factors will contribute to early diagnosis when signs of VTE appear, as well as the assessment of thromboprophylaxis if indicated. The diagnosis of VTE in patients with cancer does not differ of those who do not suffer from it. Regarding the treatment of VTE in these patients, low molecular weight heparin (LMWH), direct acting anticoagulants (DACs) and antivitamin K (VKA) are the most commonly used, although the dosing regimen and length are not clear yet. The management of these patients should be interdisciplinary and early, so the primary care physician plays a key role in this process as he/she is liaise with his/her patients. It is also necessary to update knowledge in order to improve the care of these patients. For these reasons, this document has been prepared by the Working Group on Vasculopathies of the Spanish Society of Primary Care Physicians (SEMERGEN) whose objective is to present the available information regarding the management of VTE that may appear in oncological patients, as well as the assessment of thromboprophylaxis and treatment, if appropriate, from an approach focused on a primary care field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Semergen - 49(2023), 7 vom: 15. Okt., Seite 102030 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Recomendaciones sobre enfermedad tromboembólica venosa en procesos oncológicos. Una visión desde la medicina de familia |
|---|
| Beteiligte Personen: |
García Vallejo, O [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.10.2023 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semerg.2023.102030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359876382 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359876382 | ||
| 003 | DE-627 | ||
| 005 | 20231226081817.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.semerg.2023.102030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359876382 | ||
| 035 | |a (NLM)37487423 | ||
| 035 | |a (PII)S1138-3593(23)00109-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a García Vallejo, O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recommendations for thromboembolic disease in oncological processes. A view from primary care |
| 246 | 3 | 3 | |a Recomendaciones sobre enfermedad tromboembólica venosa en procesos oncológicos. Una visión desde la medicina de familia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.10.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Venous thromboembolic disease (VTE) is a frequent complication in patients diagnosed with cancer and a cause of morbidity and mortality. Approximately 20% of thromboembolic episodes develop in association with active cancer. On the other hand, it is estimated that about 2-12% of cases, the thromboembolic episode is the first manifestation of an occult cancer, diagnosed at that time or subsequently, which offers an opportunity for early diagnosis and treatment. There are multiple factors that contribute to increase the risk of VTE in oncological patients in relation to specific characteristics of the patient, the tumor and the treatments. Knowledge of these risk factors will contribute to early diagnosis when signs of VTE appear, as well as the assessment of thromboprophylaxis if indicated. The diagnosis of VTE in patients with cancer does not differ of those who do not suffer from it. Regarding the treatment of VTE in these patients, low molecular weight heparin (LMWH), direct acting anticoagulants (DACs) and antivitamin K (VKA) are the most commonly used, although the dosing regimen and length are not clear yet. The management of these patients should be interdisciplinary and early, so the primary care physician plays a key role in this process as he/she is liaise with his/her patients. It is also necessary to update knowledge in order to improve the care of these patients. For these reasons, this document has been prepared by the Working Group on Vasculopathies of the Spanish Society of Primary Care Physicians (SEMERGEN) whose objective is to present the available information regarding the management of VTE that may appear in oncological patients, as well as the assessment of thromboprophylaxis and treatment, if appropriate, from an approach focused on a primary care field | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cáncer | |
| 650 | 4 | |a Enfermedad tromboembólica venosa | |
| 650 | 4 | |a Thromboprophylaxis | |
| 650 | 4 | |a Thrombosis | |
| 650 | 4 | |a Tratamiento | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Tromboprofilaxis | |
| 650 | 4 | |a Trombosis | |
| 650 | 4 | |a Venous thromboembolic disease | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 700 | 1 | |a Aicart Bort, M D |e verfasserin |4 aut | |
| 700 | 1 | |a Babiano Fernández, M Á |e verfasserin |4 aut | |
| 700 | 1 | |a Caballer Rodilla, J |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrera Ferriols, M Á |e verfasserin |4 aut | |
| 700 | 1 | |a Carrasco Carrasco, E |e verfasserin |4 aut | |
| 700 | 1 | |a Gil Gil, I |e verfasserin |4 aut | |
| 700 | 1 | |a Lahera García, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Martos Cárdenas, T |e verfasserin |4 aut | |
| 700 | 1 | |a Piera Carbonell, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Semergen |d 1998 |g 49(2023), 7 vom: 15. Okt., Seite 102030 |w (DE-627)NLM095511652 |x 1578-8865 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:7 |g day:15 |g month:10 |g pages:102030 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semerg.2023.102030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 7 |b 15 |c 10 |h 102030 | ||